The Need for a Global HIV Vaccine Enterprise

A new collaborative model of research is needed to increase resources, to prioritize the R agenda of the major public- and private-sector stakeholders, and ultimately to increase the probability and shorten the time to development of effective HIV vaccines for global use. The thrust of our proposal...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2003-06, Vol.300 (5628), p.2036-2039
Main Authors: Klausner, Richard D., Fauci, Anthony S., Corey, Lawrence, Nabel, Gary J., Gayle, Helene, Berkley, Seth, Haynes, Barton F., Baltimore, David, Collins, Chris, Douglas, R. Gordon, Esparza, Jose, Francis, Donald P., Ganguly, N. K., Gerberding, Julie Louise, Johnston, Margaret I., Kazatchkine, Michel D., McMichael, Andrew J., Makgoba, Malegapuru W., Pantaleo, Giuseppe, Piot, Peter, Shao, Yiming, Tramont, Edmund, Varmus, Harold, Wasserheit, Judith N.
Format: Article
Language:English
Subjects:
Academic Achievement
AIDS vaccines
Antigens
Clinical trials
Commercial regulation
Disease control
Economic regulation
HIV
Human immunodeficiency virus
Immune response
International aspects
Narcotics
Pipelines
Policy Forum
Product development
R&D
Reagents
Research & development
Vaccination
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new collaborative model of research is needed to increase resources, to prioritize the R agenda of the major public- and private-sector stakeholders, and ultimately to increase the probability and shorten the time to development of effective HIV vaccines for global use. The thrust of our proposal is (i) to increase the scale and organization for solving science problems and developing novel HIV vaccine approaches; (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified. [PUBLICATION ABSTRACT]
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1086916